IFNα has been used to treat malignant and viral disorders for more than 25 years. Its efficacy
is likely the consequence of its broad range of biologic activities, including direct effects on …

Background Afatinib is an irreversible ErbB-family blocker with preclinical activity in non-
small-cell lung cancer (NSCLC) with EGFR mutations. We aimed to assess the efficacy of …

Brain metastases are very common in lung cancer patients. The condition of these patients
is complicated and difficult to treat, and adverse reactions following treatment can affect the …

The concept of privileged structures/substructures (PS) is the idea that certain structural
features produce biological effects more often than others. The PS method can be seen as …

Targeted therapies for cancer bring the hope of specific treatment, providing high efficacy
and in some cases lower toxicity than conventional treatment. Although targeted …

The present network meta‑analysis aimed to compare the effectiveness and adverse effects
of gefitinib, erlotinib and icotinib in the treatment of patients with non‑small cell lung cancer …

Advances in the management of gliomas, including the approval of agents such as
temozolomide and bevacizumab, have created an evolving therapeutic landscape in glioma …

背景与目的: 晚期非小细胞肺癌(non-small cell lung cancer, NSCLC) 患者多程治疗失败后,
目前尚无标准的化疗方案. 本研究旨在观察贝伐单抗联合化疗治疗晚期NSCLC …

Purpose: To investigate the effects of autophagy on growth inhibition by gefitinib in non-
small cell lung cancer (NSCLC) cell lines and its probable mechanism. Methods: The mRNA …

PURPOSE: The epidermal growth factor receptor inhibitors, gefitinib and erlotinib, are used
as standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). The aim of …